-- Akebia Therapeutics (AKBA) 周一宣布，其用于治疗心脏手术相关急性肾损伤的药物 AKB-9090 的 I 期临床试验已完成首批受试者的给药。 Akebia Therapeutics 表示，该研究将评估 AKB-9090 在健康成年受试者中静脉注射给药的安全性、耐受性、药代动力学和药效学，并计划招募至多 70 名受试者。 Akebia Therapeutics 首席执行官 John Butler 在一份声明中表示，公司计划于 2027 年初公布该研究的主要数据。
Related Articles
Australia
Brazilian Rare Earths Targets Brazil Critical Minerals Province Scoping Study, Mineral Resource Estimate for Mid-2026; Shares Up 4%
Brazilian Rare Earths (ASX:BRE) said that the mineral resource estimate and scoping study for the Rocha da Rocha critical minerals province are both targeted for mid-2026, according to a Monday Australian bourse filing.Sensor-based ore sorting testing validated a simple, dry beneficiation pathway for the Monte Alto project, while a metallurgical optimization program validated low-temperature acid-cure processing at 150 degrees celsius, with a 15 kilograms blended composite scale-up test confirming high extraction performance and strong scalability, the filing said.The company expects to submit an economic development plan for the project to Brazil's National Mining Agency in the June quarter.Brazilian Rare Earths' shares rose nearly 4% in recent trading on Monday.
$ASX:BRE
Asia
CITIC Securities' Profit Surges 55% in Q1
CITIC Securities (HKG:6030, SHA:600030) posted net profit attributable to owners of 10.2 billion yuan for the first quarter of 2026, up 55% from 6.61 billion yuan a year earlier, according to an April 24 Hong Kong bourse filing.Hong Kong-listed shares of the firm were up nearly 2% in Monday morning trade.Earnings per share came in at 0.67 yuan, compared with 0.43 yuan in the prior-year period.Operating revenue rose 41% to 23.2 billion yuan from 16.4 billion yuan.
$HKG:6030$SHA:600030
Asia
NHU's Q1 Profit Rises 15%, Revenue Climbs 3%
Zhejiang NHU's (SHE:002001) net profit attributable to shareholders in the first quarter rose 15% to 6.76 billion yuan from 5.87 billion yuan a year earlier, according to a Saturday filing on the Shenzhen bourse.Earnings per share climbed 16% year on year to 2.21 yuan from 1.91 yuan.Operating revenue increased 3% to 22.3 billion yuan from 21.6 billion yuan in the prior year.
$SHE:002001